Table of Contents 3
List of Tables 5
List of Figures 5
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Albireo Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Albireo Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Albireo to Raise USD10 Million in Venture Financing 12
Partnerships 13
Biodel Enters Into Co-Development Agreement With Yichang Chang Jiang Pharma 13
Merger 14
Biodel and Albireo Merges 14
Licensing Agreements 16
Ajinomoto Pharma Amends Licensing Agreement with Albireo for Elobixibat 16
Biodel Terminates Licensing Agreement With Aegis Therapeutics For ProTek And Intravail Technologies 17
Equity Offering 18
Albireo Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 18
Albireo Pharma Raises USD74.8 Million in Public Offering of Shares 19
Albireo Pharma Raises USD52 Million in Public Offering of Shares 21
Biodel Raises USD34.5 Million in Public Offering of Shares 23
Biodel to Raise up to USD15 Million in Private Placement of Shares 25
Albireo Pharma Raises USD19.2 Million in Public Offering of Shares 27
Biodel Completes Public Offering Of Shares For US$20.5 Million 28
Biodel Completes Private Placement Of Units For US$18.5 Million 29
Asset Transactions 30
Albireo Pharma Enters into Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat 30
Albireo Pharma Inc - Key Competitors 31
Albireo Pharma Inc - Key Employees 32
Albireo Pharma Inc - Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Aug 07, 2018: Albireo reports second quarter 2018 financial results 34
May 17, 2018: Albireo Provides First Quarter 2018 Business Update 36
Mar 15, 2018: Albireo Reports Fourth Quarter and Year-End 2017 Financial Results 37
Nov 14, 2017: Albireo Reports Third Quarter 2017 Financial Results 39
Aug 21, 2017: Albireo Reports Second Quarter 2017 Financial Results 41
May 10, 2017: Albireo Reports First Quarter 2017 Financial Results 43
Mar 14, 2017: Albireo Reports 2016 Financial Results 45
Corporate Communications 47
Oct 10, 2018: Albireo appoints Simon Harford as chief financial officer and treasurer 47
Jul 25, 2018: Albireo appoints Patrick Horn as Chief Medical Officer 48
Jun 08, 2018: Albireo Names Anne Klibanski and Stephanie Okey As Board Directors 49
Sep 28, 2017: Albireo Elects Roger Jeffs to Board of Directors 50
Product News 51
05/28/2018: PIII Clinical Study Data on Chronic Constipation Treatment “GOOFICE 5mg Tablet” Will Be Presented at DDW2018 51
04/19/2018: World's First Bile Acid Transporter Inhibitor GOOFICE 5mg Tablet Launched in Japan 52
04/19/2018: Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting 53
01/19/2018: New drug approval of bile acid transporter inhibitor “GOOFICE 5mg Tablet ”for chronic constipation was obtained in Japan 54
Product Approvals 55
Feb 01, 2017: Albireo Announces Submission of New Drug Application for Elobixibat in Japan 55
Clinical Trials 56
Jul 09, 2018: Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment GOOFICE 5mg Tablet Published in The Lancet Gastroenterology & Hepatology 56
Jun 12, 2018: FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher 57
May 16, 2018: Albireo Enrolls First Patient in Phase 3 PFIC Trial of A4250 58
Apr 14, 2018: Albireo Reports Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver Disease at The International Liver Congress 2018 59
Mar 28, 2018: Albireo to Present Clinical Data on A4250 at The International Liver Congress 2018 60
Oct 20, 2017: Final Results of Albireo's Phase 2 Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting 2017 61
Oct 03, 2017: Final Results of Albireos Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting 2017 62
Sep 26, 2017: EMA's Paediatric Committee Agrees to Albireo's A4250 Pediatric Investigation Plan 63
May 18, 2017: Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC 64
Apr 27, 2017: Albireo Announces Elobixibat Data from Japan to be Presented at DDW 2017 66
Apr 22, 2017: Promising Pediatric Data for Albireo's A4250 to be Presented at The International Liver Congress 2017 67
Apr 05, 2017: EASL Selects Albireo's A4250 Data for Late Breaker Presentation 68
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69

List of Tables
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Albireo Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Albireo Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Albireo Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Albireo to Raise USD10 Million in Venture Financing 12
Biodel Enters Into Co-Development Agreement With Yichang Chang Jiang Pharma 13
Biodel and Albireo Merges 14
Ajinomoto Pharma Amends Licensing Agreement with Albireo for Elobixibat 16
Biodel Terminates Licensing Agreement With Aegis Therapeutics For ProTek And Intravail Technologies 17
Albireo Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 18
Albireo Pharma Raises USD74.8 Million in Public Offering of Shares 19
Albireo Pharma Raises USD52 Million in Public Offering of Shares 21
Biodel Raises USD34.5 Million in Public Offering of Shares 23
Biodel to Raise up to USD15 Million in Private Placement of Shares 25
Albireo Pharma Raises USD19.2 Million in Public Offering of Shares 27
Biodel Completes Public Offering Of Shares For US$20.5 Million 28
Biodel Completes Private Placement Of Units For US$18.5 Million 29
Albireo Pharma Enters into Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat 30
Albireo Pharma Inc, Key Competitors 31
Albireo Pharma Inc, Key Employees 32
Albireo Pharma Inc, Other Locations 33
Albireo Pharma Inc, Subsidiaries 33

List of Figures
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Albireo Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 10